Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Needham analyst Gil Blum has reiterated a 'Buy' rating on Autolus Therapeutics (NASDAQ: AUTL) and has maintained a price target of $10 for the stock. No additional financial figures or strategic changes were mentioned in the article.